Adriane de Andre Cardoso-Demartini, Alexsandra C Malaquias, Margaret Cristina da Silva Boguszewski
{"title":"Growth Hormone Treatment for Short Children Born Small for Gestational Age.","authors":"Adriane de Andre Cardoso-Demartini, Alexsandra C Malaquias, Margaret Cristina da Silva Boguszewski","doi":"10.17458/per.vol16.2018.dmb.ghshortchilbornsmall","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the difficulty to define born small for gestational age (SGA), being SGA has been associated with a higher risk of short stature, early-onset and rapid progression of puberty, neurocognitive dysfunctions, alterations in body composition, bone density, glucose and lipid metabolism and increased risk for cardiovascular diseases later in life. The majority of children born SGA experience spontaneous catch-up growth during the first years of life. For those who remain with short stature, treatment with recombinant human growth hormone (rhGH) may be initiated, preferably after 2-4 years of age. Response to treatment is variable. However, the benefits of rhGH go beyond increase in stature as the therapy may also improve body composition. In this review we will cover the indication and effects of GH therapy in short children born SGA.</p>","PeriodicalId":19827,"journal":{"name":"Pediatric endocrinology reviews : PER","volume":"16 Suppl 1","pages":"105-112"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric endocrinology reviews : PER","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17458/per.vol16.2018.dmb.ghshortchilbornsmall","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Despite the difficulty to define born small for gestational age (SGA), being SGA has been associated with a higher risk of short stature, early-onset and rapid progression of puberty, neurocognitive dysfunctions, alterations in body composition, bone density, glucose and lipid metabolism and increased risk for cardiovascular diseases later in life. The majority of children born SGA experience spontaneous catch-up growth during the first years of life. For those who remain with short stature, treatment with recombinant human growth hormone (rhGH) may be initiated, preferably after 2-4 years of age. Response to treatment is variable. However, the benefits of rhGH go beyond increase in stature as the therapy may also improve body composition. In this review we will cover the indication and effects of GH therapy in short children born SGA.
期刊介绍：
PEDIATRIC ENDOCRINOLOGY REVIEWS (PER) publishes scholarly review articles in all areas of clinical and experimental Endocrinology, Diabetes, Nutrition and Metabolism. PER is intended for practicing pediatricians, pediatric endocrinologists, pediatric diabetologists, pediatric gastroenterologists, neonatologists, pediatric gynecologists, nutritionists, sport physicians and pediatricians-in-training.
PER will also publish topics on specific subjects or as proceedings of scientific meetings in the above fields of interest. All articles, whether invited or direct contributions, are peer-reviewed. PER publishes correspondence, book reviews, a meeting calendar and meeting reports.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
